Karen S. Mccoy

Pediatric Pulmonology

700 Childrens Dr
Columbus, OH 43205

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 84 publications

Real-world efficacy, safety and heterogenicity of efficacy of elexacaftor-tezacaftor-ivacaftor in younger children (6-11 years old) with cystic fibrosis.

Real-world efficacy, safety and heterogenicity of efficacy of elexacaftor-tezacaftor-ivacaftor in younger children (6-11 years old) with cystic fibrosis.

Journal: Respiratory medicine

Published: April 06, 2026

Real-world Efficacy, Safety and Heterogenicity of Efficacy of Elexacaftor-Tezacaftor-Ivacaftor in Younger Children (6-11 Years Old) with Cystic Fibrosis.

Real-world Efficacy, Safety and Heterogenicity of Efficacy of Elexacaftor-Tezacaftor-Ivacaftor in Younger Children (6-11 Years Old) with Cystic Fibrosis.

Journal: Respiratory medicine

Published: April 06, 2026

A Precious Child's Legacy: Insights Into Advanced Lung and Liver Disease in Children With Cystic Fibrosis.

A Precious Child's Legacy: Insights Into Advanced Lung and Liver Disease in Children With Cystic Fibrosis.

Journal: Pediatric pulmonology

Published: November 20, 2025

Highly Effective Modulator Therapies Restore Neutrophil Dysfunction in People with Cystic Fibrosis.

Highly Effective Modulator Therapies Restore Neutrophil Dysfunction in People with Cystic Fibrosis.

Journal: American journal of respiratory cell and molecular biology

Published: September 23, 2025

CFTR mutation leads to intrinsic dysfunction in neutrophils from people with Cystic Fibrosis.

CFTR mutation leads to intrinsic dysfunction in neutrophils from people with Cystic Fibrosis.

Journal: bioRxiv : the preprint server for biology

Published: June 12, 2025

De-escalation of Medications After Initiation of Elexacaftor-Tezacaftor-Ivacaftor in Children 6 to 11 Years of Age With Cystic Fibrosis.

De-escalation of Medications After Initiation of Elexacaftor-Tezacaftor-Ivacaftor in Children 6 to 11 Years of Age With Cystic Fibrosis.

Journal: The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Published: April 22, 2025

Real -world impact of previous exposure to CFTR modulators on clinical parameters and chronic sinus disease in people with cystic fibrosis on elexacaftor-tezacaftor-ivacaftor.

Real -world impact of previous exposure to CFTR modulators on clinical parameters and chronic sinus disease in people with cystic fibrosis on elexacaftor-tezacaftor-ivacaftor.

Journal: Respiratory medicine

Published: March 24, 2025

Intermittent Asthma and Risk of Severe Exacerbation in Children.

Intermittent Asthma and Risk of Severe Exacerbation in Children.

Journal: Chest

Published: March 17, 2025

A New Simple to Use Chest CT Scoring System: Validation Study.

A New Simple to Use Chest CT Scoring System: Validation Study.

Journal: Pediatric pulmonology

Published: February 07, 2025

Real-life impact of genotype and severity of lung disease on efficacy of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis.

Real-life impact of genotype and severity of lung disease on efficacy of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis.

Journal: Pulmonary pharmacology & therapeutics

Published: November 12, 2024

Flow cytometric measurement of CFTR-mediated chloride transport in human neutrophils.

Flow cytometric measurement of CFTR-mediated chloride transport in human neutrophils.

Journal: Journal of leukocyte biology

Published: July 31, 2024

Edinburgh postnatal depression scale score elevation in caregivers of infants with cystic fibrosis.

Edinburgh postnatal depression scale score elevation in caregivers of infants with cystic fibrosis.

Journal: Pediatric pulmonology

Published: June 09, 2024

Showing 1-12 of 84

Last Updated: 09/26/2026